$Yili Chuanning Biotechnology (301301.SZ)$ According to Twin...

According to Twining Biotech's performance forecast, the average sales prices of erythromycin thiocyanate, 6-APA, and penicillus G potassium salt increased by 17.74%, 41.87% and 56.93% respectively during the reporting period, and shutdown losses due to the 2022 pandemic decreased by 48.45% compared to 2021. The company is expected to achieve net profit attributable to shareholders of listed companies of 390 million yuan to 430 million yuan in 2022, an increase of 250.26% to 286.18% over the same period last year.